Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Transnasal delivery of the peptide to the brain

  • At: Stockholm (Sweden) (2017)
  • Type: Poster
  • By: TANAKA, Akiko (Kyoto, Japan)
  • Co-author(s): Akiko Tanaka: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Chiaki Maeda: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Mayumi Amano: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Kentaro Takayama: Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Yoshio Hayashi: Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
    Daisuke Inoue: School of Pharmacy, Shujitsu University, Okayama, Japan
    Tomoyuki Furubayashi: School of Pharmacy, Shujitsu University, Okayama, Japan
    Kosuke Kusamori: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Hidemasa Katsumi: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Toshiyasu Sakane: Department of Pharmaceutical Technology, Kobe Pharmaceutical University, Kobe, Japan;Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Akira Yamamoto: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  • Abstract:

    Backgrounds

    The obesity and the metabolic syndrome have prevailed all over the world. Recently, CPN-116 (CPN), which is a specific agonist peptide to neuromedin U receptor 2 (NMUR2), has been developed as a new therapeutic candidate for the treatments of obesity. The treatment with CPN will be unlikely successful due to the limited delivery to the..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses